Protocol Ledger

NCT03606174 · Phase II · TERMINATED

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Interventional Phase II clinical trial protocol NCT03606174 sponsored by Bristol Myers Squibb in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-09-11 Enrollment: 260 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03606174
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)260 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03606174
Protocol FieldVerified Registry Value
NCT IdentifierNCT03606174
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment260 participants (ACTUAL)
Registered Start Date2018-09-11
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI